Glioblastoma target volumes change substantially during MR-guided radiotherapy, often within the first week
Serial MR-linac imaging showed frequent glioblastoma target changes, with some extending beyond the planned CTV and 95% isodose.
Tag
glioblastoma
NRG-BN010 immuno-RT combination failed to improve response in recurrent glioblastoma
Tocilizumab, atezolizumab and 24 Gy/3-fraction FSRT produced only a 3.4% objective response rate in recurrent glioblastoma.
Comprehensive radiotherapy tracked with longer survival in recurrent glioblastoma leptomeningeal dissemination
In recurrent IDH-wildtype glioblastoma LMD, comprehensive RT and systemic therapy were independently associated with longer survival.
Tumor-spread modeling enabled anisotropic glioblastoma treatment planning beyond MRI-visible disease
Model-predicted microscopic glioblastoma spread could be incorporated into clinically deliverable plans, but dose-painting accuracy deteriorated as target complexity increased.
Five-parameter model reproduced physician-specific glioma CTV contouring patterns
In 93 glioma cases, a five-parameter CTV model reproduced physician contours and achieved similar blinded clinical quality ratings.
VMAT exposed less circulating blood than IMRT in glioma simulations
VMAT exposed less circulating blood than IMRT, but modeled immune-cell depletion differed by only one percentage point after 30 fractions.
Metformin reshaped glioblastoma immunity and improved radiotherapy response in mice
Metformin plus radiotherapy prolonged survival in two syngeneic glioblastoma models while shifting macrophage and T-cell populations toward antitumor phenotypes.
Most glioblastoma recurrences clustered within 10 mm of the original GTV
In 201 recurrent glioblastomas, 80% required no more than 10.4 mm expansion to encompass 80% of recurrence volume.
Cannabinoids reduced glioblastoma apoptosis after chemotherapy and radiation in vitro
Several cannabinoids reduced therapy-induced glioblastoma apoptosis and enhanced clonogenic survival in vitro, raising concern about concurrent use during treatment.
Six-fraction chemoradiation worsened survival in newly diagnosed glioblastoma
Six-fraction chemoradiation shortened median survival from 21 to 13 months and substantially increased radiation necrosis compared with standard treatment.
Modelled actinium-225 delivery reduced glioblastoma clonogens but had limited spatial reach
Convection-enhanced actinium-225 markedly reduced modelled clonogenic survival, but effective coverage extended only about 1.4 cm from each catheter.
Glioblastoma brachytherapy remains limited by non-standardized dosimetry
Modern intracavitary platforms can intensify pericavitary dose immediately after surgery, but standardized patient-specific dosimetry and comparative clinical evidence remain lacking.
Bragg peak proton FLASH matched CyberKnife plans and cut beam delivery to seconds
In 10 recurrent glioblastoma replans, Bragg peak proton FLASH improved conformity and reduced estimated beam delivery from approximately 17 minutes to under two seconds.
IGF1R blockade overcame oHSV and radiotherapy resistance in glioblastoma and breast cancer models
Triple oHSV, radiotherapy and IGF1R blockade suppressed YAP1, produced tumour regressions and prolonged survival in glioblastoma and breast cancer models.
Higher-dose iodine-125 brachytherapy was associated with longer survival in recurrent glioblastoma
Iodine-125 doses of 140–160 grays were associated with longer median survival than 120–140 grays in recurrent glioblastoma.